Gabrilove J L, Levine A C, Kirschenbaum A, Droller M
J Clin Endocrinol Metab. 1987 Jun;64(6):1331-3. doi: 10.1210/jcem-64-6-1331.
To determine the effects of reversible medical castration on prostatic size in patients with benign prostatic hypertrophy (BPH), 3 patients with BPH were treated with a GnRH analogue, leuprolide, for six months at a dosage of .2ml (1 mg) s.c. daily. Serum testosterone, dihydrotestosterone and estradiol fell to castration levels 4-6 weeks after the initiation of treatment and remained low throughout the study period. Transrectal ultrasonography of the prostate demonstrated an average decrease in prostatic volume of 58% at 6 months, with the greatest rate of decrease occurring during the 2nd to 5th months of treatment. One man who had acute urinary retention before treatment was subsequently able to void extremely well. In a second man the symptoms of prostatism diminished but in the third urinary frequency and nocturia persisted in spite of a reduction in prostatic size, presumably because his symptoms were due to renal insufficiency.
为确定可逆性药物去势对良性前列腺增生（BPH）患者前列腺大小的影响，3例BPH患者接受促性腺激素释放激素（GnRH）类似物亮丙瑞林治疗，皮下注射剂量为每日0.2ml（1mg），为期6个月。治疗开始后4 - 6周，血清睾酮、双氢睾酮和雌二醇降至去势水平，并在整个研究期间维持在低水平。经直肠前列腺超声检查显示，6个月时前列腺体积平均减少58%，最大减少率出现在治疗的第2至5个月。1例治疗前有急性尿潴留的男性患者随后排尿情况极佳。第2例患者前列腺增生症状减轻，但第3例患者尽管前列腺体积减小，尿频和夜尿症状仍持续存在，推测其症状是由肾功能不全所致。
